

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



GenFleet Therapeutics (Shanghai) Inc.

勁方醫藥科技(上海)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2595)

VOLUNTARY ANNOUNCEMENT INCLUSION AS A CONSTITUENT OF HANG SENG INDEX SERIES AND MSCI INDEX

This announcement is made by GenFleet Therapeutics (Shanghai) Inc. (the “**Company**” or “**GenFleet**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that the Company will be included as a constituent of Hang Seng Index Series, including the Hang Seng Composite Index (HSCI), Hang Seng Stock Connect Hong Kong Index, and Hang Seng Innovative Drug Index, according to the quarterly review results published by Hang Seng Indexes Company Limited on February 13, 2026. The adjustment will take effect officially on March 9, 2026. Additionally, the Company will also be included as a constituent of the MSCI Global Small Cap Index, according to the quarterly review results announced recently by Morgan Stanley Capital International (MSCI), with the adjustment taking effect after the close of trading on February 27, 2026.

The Hang Seng Composite Index, as a comprehensive H-share benchmark, covers the top 95% of listed companies by cumulative market capitalization on the HKEX Main Board and is widely used by index funds, mutual funds, and performance evaluation systems. Inclusion into the HSCI will allow the Company to join the eligible shares list of the Shanghai-Hong Kong Stock Connect and the Shenzhen-Hong Kong Stock Connect for trading with investors in the Chinese mainland.

According to Hang Seng Indexes Company Limited’s quarterly review results, the H-shares of the GenFleet will also be selected for other Hang Seng Index components, including Hang Seng Composite MidCap & SmallCap Index, Hang Seng Composite SmallCap Index, Hang Seng Small Cap (Investable) Index, Hang Seng SCHK Mainland China Companies Index, Hang Seng Stock Connect Hong Kong MidCap & SmallCap Index, Hang Seng Stock Connect Hong Kong SmallCap Index, Hang Seng SCHK Innovative Drug Index, Hang Seng SCHK Innovative Drug Select Index, Hang Seng SCHK Pharmaceuticals & Biotechnology (Investable) Index, the Hang Seng Composite Industry Index – Healthcare and Hang Seng Healthcare Index, and Hang Seng Healthcare Index.

The Board believes the inclusion of the Company's shares into multiple major indices reflects investors' recognition of the Company's sustained value and potential. It's expected to further improve the stock liquidity, broaden investor base with diversified shareholder composition, and promote the Company's development in the long run. The Board appreciates the continued support from shareholders and investors; the Company will strengthen its leading advantage in RAS – targeted therapeutics as well as competitiveness in developing other innovative treatments, to drive sustainable value creation through proven R&D capabilities and to expand its market presence while advancing corporate responsibilities for patients and society.

About the Company

The Company is a biopharmaceutical company based in China focusing on bringing new and effective treatment options in the fields of oncology, autoimmune and inflammatory diseases to uphold our mission of addressing unmet medical needs around the globe. The Company adheres to an innovative development strategy, with a vision to propel us with the advancement of science and technology to build a globally competitive biopharmaceutical company. The Company has established and leveraged a proven, integrated research and development platform spanning target discovery, molecular discovery and evaluation, translational science and clinical development, as well as key manufacturing aspects including formulation research, process development and quality analysis. Our technological capabilities include discovery of new molecular entities, novel molecular modalities, investigation of molecular process routes and quality standards, as well as exploration of differentiated clinical development strategy and pathway. Combining these internally accumulated capabilities and external resources of our collaborators and service providers, the Company has rendered our pipeline products among the frontrunners in both China and the global market, resulting in potentially significant market opportunities and commercial value.

GLOSSARY OF TECHNICAL TERMS

“RAS” ras sarcoma, a family of proteins that are critical regulators of cellular signaling pathways; it primarily includes HRAS, KRAS, and NRAS

By order of the Board
GenFleet Therapeutics (Shanghai) Inc.
Dr. Qiang LU
Chairman and Executive Director

Hong Kong, February 13, 2026

As at the date of this announcement, the Board of the Company comprises: (i) Dr. Qiang LU, Dr. Jiong LAN and Ms. ZHANG Wei as executive directors; (ii) Mr. ZHU Jingyang and Ms. TAO Sha as non-executive directors; and (iii) Ms. Christine Shaohua LU-WONG, Dr. ZHOU Demin and Mr. LI Bo as independent non-executive directors.